4 Analysts Have This To Say About Agios Pharmaceuticals - Agios Pharmaceuticals (NASDAQ:AGIO)

In the latest quarter, 4 analysts provided ratings for Agios Pharmaceuticals (NASDAQ:AGIO), showcasing a mix of bullish and bearish perspectives.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

	Somewhat Bullish	Indifferent
Total Ratings	3	1
Last 30D	1	0
1M Ago	1	1
2M Ago	0	0
3M Ago	1	0

Analysts have recently evaluated Agios Pharmaceuticals and provided 12-month price targets. The average target is $54.25, accompanied by a high estimate of $56.00 and a low estimate of $51.00. A decline of 3.12% from the prior average price target is evident in the current average.

Interpreting Analyst Ratings: A Closer Look

The standing of Agios Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Danielle Brill	Raymond James	Announces	Outperform	$51.00	-
Andrew Berens	Leerink Partners	Lowers	Market Perform	$56.00	$60.00
Gregory Renza	RBC Capital	Maintains	Outperform	$55.00	$55.00
Gregory Renza	RBC Capital	Raises	Outperform	$55.00	$53.00

Key Insights:

Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Agios Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Agios Pharmaceuticals compared to the broader market.
Price Targets: Analysts predict movements in price targets, offering estimates for Agios Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

For valuable insights into Agios Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Agios Pharmaceuticals analyst ratings.

Unveiling the Story Behind Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Key Indicators: Agios Pharmaceuticals's Financial Health

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Agios Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 28.35%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Agios Pharmaceuticals's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1115.71%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -13.69%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.85%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: With a below-average debt-to-equity ratio of 0.1, Agios Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.

What Are Analyst Ratings?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGIOAgios Pharmaceuticals Inc

$32.92-%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.